NICE guidance on azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia

MeSH terms

• Antimetabolites, Antineoplastic* / therapeutic use
• Azacitidine* / therapeutic use
• Cost-Benefit Analysis
• Humans
• Leukemia, Myeloid, Acute* / drug therapy
• Leukemia, Myelomonocytic, Chronic* / drug therapy
• Myelodysplastic Syndromes* / drug therapy
• Practice Guidelines as Topic
• Quality-Adjusted Life Years